RESUMO
Introducción. La enfermedad de Parkinson es la segundaenfermedad neurodegenerativa más frecuente. Objetivo. Analizar la dispensación de fármacos antiparkinsonianos en las diferentes comunidades autónomas españolas y estimar la prevalencia de la enfermedad en las mismas. Materiales y métodos. Se han estudiado las dispensaciones de antiparkinsonianos en España durante dos años (de octubre 1998 a septiembre de 2000), calculando lasdosis diarias definidas por mil habitantes y día (DHD). La DHD de levodopa ha permitido estimar la prevalencia de la enfermedad. El gasto se ha expresado en coste por mil habitantes y día (CHD) y en coste por tratamiento y día. Resultados. El fármaco más utilizado es levodopa, seguido de biperideno y selegilina. El coste total durante el período de estudio fue de 116.346.589,30 euros. El CHDse cifró en 4,14 euros. En el coste por tratamiento y día de los diferentes fármacos destaca el elevado coste de pramipexol y entacapona. La prevalencia de enfermedad de Parkinson en España se estima en 1,7; se observa una variabilidad geográfica importante, con cifras de prevalencia más altas en Castilla-León, Galicia y LaRioja, y cifras inferiores en Andalucía y Murcia. En cifras absolutas, el número de enfermos en España se puede estimar en 69.571 personas. Conclusión. Se encuentran diferencias en la utilización de fármacos antiparkinsonianos en las diferentes comunidades autónomas
Introduction. Parkinsons disease is the second most frequent neurodegenerative disease. Aim. To analyze thedispensation of antiparkinsonian agents in Spain and to estimate the Parkinsons disease prevalence. Materials and methods. Dispensation of antiparkinsonian agents were studied in Spain during two years (October 1998 to September 2000). Results were expressed in defined daily dosages per 1,000 inhabitants per day (DID). Levodopas DID was used to estimate the prevalence of the disease. The cost per 1,000 inhabitants per day (CID) and the daily treatment cost was also valued. Results. The most frequently used drugs are levodopa, biperiden and selegiline. The total cost reached values of 116,346,589.30 euros during the study period. The CID was 4,14 euros. It was very high the daily treatment cost of pramipexol and entacapone. The prevalence of Parkinsons disease is considered in 1.7 per 1,000 inhabitants in Spain. There is an important geographical variability; regions as Castilla-Leon, Galicia and La Rioja have a higher prevalence than Andalucia or Murcia. The numberof patients in Spain can be considered in 69,571 people. Conclusion. There are some differences between the autonomous communities in the antiparkinsonian drugs utilization
Assuntos
Humanos , Doença de Parkinson/epidemiologia , Antiparkinsonianos/uso terapêutico , Estudos Retrospectivos , Custos de Medicamentos , Efeitos Psicossociais da Doença , Uso de Medicamentos/economia , Farmacoepidemiologia , Prevalência , Espanha/epidemiologiaRESUMO
INTRODUCTION: Parkinson's disease is the second most frequent neurodegenerative disease. AIM: To analyze the dispensation of antiparkinsonian agents in Spain and to estimate the Parkinson's disease prevalence. MATERIALS AND METHODS: Dispensation of antiparkinsonian agents were studied in Spain during two years (October 1998 to September 2000). Results were expressed in defined daily dosages per 1,000 inhabitants per day (DID). Levodopa's DID was used to estimate the prevalence of the disease. The cost per 1,000 inhabitants per day (CID) and the daily treatment cost was also valued. RESULTS: The most frequently used drugs are levodopa, biperiden and selegiline. The total cost reached values of 116,346,589.30 euros during the study period. The CID was 4,14 euros. It was very high the daily treatment cost of pramipexol and entacapone. The prevalence of Parkinson's disease is considered in 1.7 per 1,000 inhabitants in Spain. There is an important geographical variability; regions as Castilla-Leon, Galicia and La Rioja have a higher prevalence than Andalucia or Murcia. The number of patients in Spain can be considered in 69,571 people. CONCLUSION: There are some differences between the autonomous communities in the antiparkinsonian drugs' utilization.
